Cryoablation Devices; Help Destroy Cancer Cells and Treat Non-Tumor Diseases Affecting the Heart

Cryoablation Devices

Cryoablation devices are currently used to treat benign and malignant tumors of the prostate, liver, lung, kidney, bone, and breast, as well as non-tumor diseases relating to the heart. Cryoablation is a minimally invasive interventional radiology procedure, type of cryotherapy, which uses extreme cold to freeze and kill abnormal cancerous and precancerous cells. The application of cold to tumor cells prevents further growth or spreading, making this an effective outpatient treatment for cancer. Cryoablation is a procedure in which an extremely cold liquid or an instrument called a cryoprobe is used to freeze and destroy abnormal tissue.

Although cryoablation has been used to treat malignancy in a wide variety of organs, including the eye, brain, head/neck, and esophagus, in current practice it is most commonly used in the treatment of benign and malignant tumors. Cryoablation devices is a minimally invasive, image-guided therapy that destroys cancer cells using extreme cold. It can also be used to treat non-tumor diseases affecting the heart. During the procedure, a specialist touches the tissue with a cryoprobe, which has the tip that freezes and destroys abnormal or diseased cells. The cold from the cryoprobe damages cell’s DNA, energy-producing mitochondria, and cytoskeleton.

The Global Cryoablation Devices Market Size was valued at US$ 132.4 million in 2018, and is expected to exhibit a CAGR of 8.5% over the forecast period (2023–2027).

A cryoprobe is cooled with substances such as liquid nitrous oxide, liquid nitrogen, or compressed argon gas. Cryoablation may be used to treat certain types of cancer and some conditions that may become cancer. Cryoablation is generally very safe. However, there are some risks, particularly with percutaneous or surgical cryoablation, such as complications from anesthesia, fluid collection in surrounding areas, bleeding, damage to surrounding structures, weakness or numbness due to a nerve damage, and infection from any opening in the skin. Cryoablation is a safe procedure with many benefits; has high success in stopping the growth or spread of cancerous cells.

Thus, there is an increase in demand for cryoablation devices worldwide. In June 2021, Medtronic obtained expanded approval from the U.S. Food and Drug Administration (USFDA) for its Arctic Front Family of Cardiac Cryoablation Catheters to treat recurrent symptomatic paroxysmal atrial fibrillation (AF).